Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.45 and traded as high as $13.62. Global X Genomics & Biotechnology ETF shares last traded at $13.60, with a volume of 2,390 shares traded.
Global X Genomics & Biotechnology ETF Stock Up 1.7 %
The firm's 50-day moving average is $13.01 and its two-hundred day moving average is $13.45.
Get Global X Genomics & Biotechnology ETF alerts:Institutional Trading of Global X Genomics & Biotechnology ETF
Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Global X Genomics & Biotechnology ETF by 518.3% during the 3rd quarter. Royal Bank of Canada now owns 187,751 shares of the company's stock valued at $2,357,000 after acquiring an additional 157,385 shares during the last quarter. One Capital Management LLC grew its holdings in shares of Global X Genomics & Biotechnology ETF by 0.6% in the 3rd quarter. One Capital Management LLC now owns 415,101 shares of the company's stock valued at $5,209,000 after buying an additional 2,422 shares during the period. Envestnet Asset Management Inc. acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter valued at $208,000. Nomura Asset Management Co. Ltd. boosted its stake in Global X Genomics & Biotechnology ETF by 49,700.0% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 49,800 shares of the company's stock worth $625,000 after purchasing an additional 49,700 shares during the period. Finally, Simplex Trading LLC boosted its stake in Global X Genomics & Biotechnology ETF by 198.6% in the 3rd quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock worth $29,000 after purchasing an additional 1,537 shares during the period.
Global X Genomics & Biotechnology ETF Company Profile
(Get Rating)Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Featured Articles
- Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.